Life Sciences investment firm typically allocates up to $4M per initial investment. With follow-on allocations, the total investment can reach up to $10M per company. The firm takes a mid-to-long-term investment approach. The firm typically syndicates with major US venture capital firms. The firm is currently seeking new opportunities in the US, Canada, and Western Europe.
The firm puts 60% focus on therapeutics and 40% on medical devices, diagnostics and digital health. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor 20% interest in early-stage breakthrough bioengineering platforms with strong management teams. In medtech and digital health, the firm seeks to provide growth funding in technologically de-risked stories in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric. Lab equipment, medical services facilities and health tech, and biosimilars/generics/reformulations are not of interest.
The firm focuses on five key disease areas: oncology, autoimmune diseases, anti-infectives, CNS/pain, and women’s health. In oncology and autoimmune diseases, the firm seeks therapies with novel mechanisms of action, human data and signs of efficacy, and it also considers new generation molecular diagnostics technologies. In anti-infectives, the firm is considering early stage assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and a clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which predominantly help women give birth to healthy children.
The firm is looking for high-caliber serial entrepreneurs with an unmatched track-record of success and strong credibility. The firm does not typically take a board seat in the companies it invests in.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply